Immunotherapy / PD-1 inhibitorInvestigationalInvestigational
Dostarlimab
How it works
Blocks the action of programmed death-1 (PD-1), a protein that helps cancer cells evade the immune system. By blocking PD-1, dostarlimab allows the immune system to recognize and attack cancer cells.
Cancer types
Colorectal Cancer— All patients
Ovarian Cancer— PD-L1-positive
Efficacy
In clinical trials, dostarlimab, in combination with chemotherapy, improved overall response rate in patients with ovarian cancer, with a response rate of approximately 80%.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| New Treatment Combination Shows Modest Progression-Free Survival Benefit in Advanced Ovarian Cancer | Ovarian Cancer | phase-3 | The primary endpoint was investigator-assessed progression-free survival (PFS) as per RECIST v1.1, with a median of 20.6 months in arm 3 versus 19.2 months in arm 2. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.